Scholarlink

<p>Lyme disease (LD) cases have doubled globally. LD is a tick-borne illness caused by the <i>Borrelia burgdorferi sensu lato</i> (Bb). If untreated, Bb can disseminate to distal organs, causing carditis, arthritis, and meningitis. Currently, no FDA-approved human LD vaccine exists on the market. This study used two approaches to incorporate OspA into the rabies virus (RABV) vaccine vector. We used the RABV-glycoprotein tail (RVG tail) and the Hendra virus (HeV) glycoprotein tail (HVG tail) to incorporate OspA, creating BNSP333-OspA-RVG and BNSP333-OspA-HVG, respectively. Both vaccines produced type-1 biased anti-OspA antibodies, but only BNSP333-OspA-HVG induced neutralizing antibodies and protected against Bb infection. Furthermore, BNSP333-OspA-HVG was combined with an established LD vaccine, BNSP333-BBI39-dRVG, to study a multivalent LD vaccine. The single and multivalent vaccines produced robust type-1 biased humoral responses and induced protection against Bb after short-term and long-term tick challenge experiments. These findings contributed to the development of future LD vaccines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rabies virus-vectored Lyme disease vaccine provides long-term protection against tick-transmitted Borrelia burgdorferi

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Shantel Rios,
  • Bibek Bhattachan,
  • Christoph Wirblich,
  • Anisha Chandwani,
  • Kruthi Vavilikolanu,
  • Jacob F. Myers,
  • Chrysoula Kitsou,
  • Utpal Pal,
  • Matthias J. Schnell

摘要

Lyme disease (LD) cases have doubled globally. LD is a tick-borne illness caused by the Borrelia burgdorferi sensu lato (Bb). If untreated, Bb can disseminate to distal organs, causing carditis, arthritis, and meningitis. Currently, no FDA-approved human LD vaccine exists on the market. This study used two approaches to incorporate OspA into the rabies virus (RABV) vaccine vector. We used the RABV-glycoprotein tail (RVG tail) and the Hendra virus (HeV) glycoprotein tail (HVG tail) to incorporate OspA, creating BNSP333-OspA-RVG and BNSP333-OspA-HVG, respectively. Both vaccines produced type-1 biased anti-OspA antibodies, but only BNSP333-OspA-HVG induced neutralizing antibodies and protected against Bb infection. Furthermore, BNSP333-OspA-HVG was combined with an established LD vaccine, BNSP333-BBI39-dRVG, to study a multivalent LD vaccine. The single and multivalent vaccines produced robust type-1 biased humoral responses and induced protection against Bb after short-term and long-term tick challenge experiments. These findings contributed to the development of future LD vaccines.